Re: CDK inhibitors as potential therapeutics for ER+/ and/or Her2+ bc
Looks like CDK inhibitors are still in early trials? I like the idea of synergy with Tamoxifen and Herceptin. Considering Tamoxifen can affect both Er+ and ER-, could be a great lower toxicity approach. Amen.
|